The Effect of a Novel Combined Hormonal Treatment Containing a GnRH-antagonist for Uterine Fibroids and Endometriosis on Hemostasis Parameters: a Prospective Cohort Study

Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and/or menstrual pelvic pain and abnormal uterine bleeding. The first-line management of these conditions relies on medical treatment. Hormonal treatment with contraceptive pill can be effective, although up to 30% of patients do not respond to this line of treatment. In this context, GnRH antagonists have been introduced. By suppressing ovulation, they inhibit the action of the gonadal axis and thus can reduce bleeding and pain associated with uterine fibroids and endometriosis. More recently, the GnRH antagonist known as Relugolix has been associated with a low-dose oestradiol and progesteron-line molecule, a medication known as Ryeqo. The goal of this type of treatment is to suppress ovulation while also minimizing symptôms which may derive from lack of oestrogen and progesterone in reproductive age women.
While Ryeqo's efficacy has been proven by multiple large randomized controlled trials, its impact on blood coagulation has yet to be determined. Venous thromboembolism (VTE) is the main, potentially fatal, dleterious effect of oestrogen-containing hormonal treatmen, such as combined oral contraceptives (COC). Several epidemiological studies have found a 3-6 increase in the risk of VTE among women on COC. The thrombogenic risk can be assessed by measuring specific blood biomarkers, which are known to be correlated to the thrombogenic phenotype and allow an overview of the VTE risk prior to conducting large population-scale studies directly measuring the adverse event's prevalence.
The aim of this study is to document the effects of Ryeqo® on hemostasis parameters in order to estimate the risk of VTE associated with its employ. An improved understanding of the VTE risk associated with Ryeqo® will allow to adapt hormonal treatment based on each woman's personal risk profile.
The study will be explained to all women whose medical condition allows the prescription of Ryeqo. All women who give their consent to participate in the study will have a urinary pregnancy test and a blood sample drawn before beginning treatment with Ryeqo. A second visit will be scheduled at 3 months, throughout which a second blood sample will be drawn. A questionnaire including socio-demographic data and clinical symptoms will be completed both on the first and the second visit.

开始日期2025-09-30

申办/合作机构

Les Hôpitaux Universitaires de Genève

NCT06953076

/ RecruitingN/AIIT

MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study

Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.
Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.

开始日期2025-05-02

申办/合作机构-

NCT05739136

/ Active, not recruitingN/A

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.

开始日期2025-04-30

申办/合作机构

Sumitomo Pharma Co., Ltd.

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的临床结果

登录后查看更多信息

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的转化医学

登录后查看更多信息

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的专利（医药）

登录后查看更多信息

项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的文献（医药）

2025-09-01·FERTILITY AND STERILITY

Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2

Article

作者: Bouzegaou, Nadia ; Stewart, Elizabeth A ; Rakov, Viatcheslav G ; Venturella, Roberta ; Catherino, William H ; Vannuccini, Silvia ; Zaim, Souhil ; Munro, Malcolm G ; Perry, Julie S ; Wu, Rui ; Al-Hendy, Ayman

OBJECTIVE:

To assess the effects of relugolix combination therapy in women with uterine fibroids (UFs) and concomitant ultrasound-diagnosed adenomyosis.

DESIGN:

This post hoc analysis used pooled data from completers of the pivotal LIBERTY studies. The subgroup of women with adenomyosis and UFs was compared with the overall study population on selected efficacy and safety endpoints.

SUBJECTS:

Premenopausal women (aged 18-50 years) with diagnosed UFs (confirmed by ultrasonography) and heavy menstrual bleeding (assessed by the alkaline hematin method).

INTERVENTION:

Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) or placebo for 24 weeks, or delayed relugolix combination therapy (40 mg of relugolix monotherapy for 12 weeks, followed by relugolix combination therapy for 12 weeks).

MAIN OUTCOME MEASURES:

Endpoints included the percentage of women with concomitant adenomyosis, the proportion of treatment responders (achieved or maintained a menstrual blood loss <80 mL and ≥50% reduction in menstrual blood loss volume from baseline over the last 35 days of treatment), the proportion of women achieving or maintaining amenorrhea over the last 35 days of treatment, and the change from baseline to week 24 in uterine volume and adverse events.

RESULTS:

A total of 111 women (18.2%) had a baseline diagnosis of concomitant adenomyosis (37 in the relugolix combination therapy group, 45 in the delayed relugolix combination therapy group, 29 in the placebo group) and were included in this analysis. Of women with adenomyosis, 83.8% in the relugolix combination therapy group were treatment responders compared with 27.6% in the placebo group. Amenorrhea was achieved in 64.9% of women with adenomyosis treated with relugolix combination therapy and in 6.9% of women treated with placebo. The least square mean uterine volume of women with adenomyosis decreased by 22.2% and 5.8% in the relugolix combination therapy and placebo groups, respectively. Results for the above outcomes in the relugolix combination therapy population were similar to the delayed relugolix combination therapy group.

CONCLUSION:

Efficacy outcomes in women with adenomyosis and UFs were comparable with those in women from the overall LIBERTY study population.

CLINICAL TRIAL IDENTIFICATION NUMBER:

LIBERTY 1, 2016-003727-27 (EudraCT) and NCT03049735; LIBERTY 2, 2016-005113-50 (EudraCT) and NCT03103087.

2025-01-01·Drug and therapeutics bulletin

▼Ryeqo for treatment of uterine fibroids

Article

2024-04-01·Drugs

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Review

作者: Blair, Hannah A

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree^® (USA); Ryeqo^® (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to severe pain associated with endometriosis in premenopausal women and in the EU for the symptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, while the addition of estradiol/norethisterone acetate mitigates hypoestrogenic effects including bone mineral density (BMD) loss and vasomotor symptoms. In two pivotal phase III trials, relugolix combination therapy significantly improved dysmenorrhoea and non-menstrual pelvic pain in premenopausal women with moderate to severe endometriosis. The combination also reduced overall pelvic pain and dyspareunia, reduced analgesic and opioid use, and improved health-related quality of life. The efficacy of relugolix combination therapy was sustained over the longer term (up to 2 years). Relugolix combination therapy was generally well tolerated and BMD loss over time was minimal. With the convenience of a once daily oral dosing regimen, relugolix combination therapy is a valuable addition to the options currently available for the management of endometriosis-associated pain.

项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的新闻（医药）

2026-01-26

·药通社

一药多效，国家鼓励仿制！

此前我们对2025年仿制药临床批件数量进行了盘点：这些品种，免不了大临床？！出乎意料，2025仿制药获得最多临床批件的品种竟是一款固体制剂，一年获得批件达7张，这一品种就是瑞卢戈利片。 ↓ 扫码加入药通社交流群 ↓ 瑞卢戈利片由日本武田研发，是一种口服的促性腺激素释放激素（GnRH）受体拮抗剂，可用于治疗子宫肌瘤、子宫内膜异位症，还可治疗前列腺癌等。此品种于2023年12月被纳入《第三批鼓励仿制药品目录》，自此之后意图仿制的企业就很多。由于武田并未在国内上市，因此该品仿制需完成BE+Ⅲ期临床试验。截至目前，共有11家企业获得了临床批件，仅2025年就有7家，包括齐鲁、振东、民生、康恩贝等众多知名药企。图源：摩熵医药进度最快的是江西山香药业，于2023年11月获批临床，用于治疗成人晚期前列腺癌患者，实际入组120人，2025年11月17试验完成。而后12月29日，压着年尾，江西山香药业（120mg）率先提交了上市申请，首仿之争正式开启。值得注意的是，这个品种有两种规格及复方。不同的规格，具有不同的适应症，且对应不同的商品名。瑞卢戈利片由武田制药研发，2019年，瑞卢戈利片40mg规格在日本上市，用于改善子宫肌瘤引起的月经过多、下腹痛、腰痛和贫血等症状，此规格目前只在日本有上市，上市后武田未公布过销售数据。 2020年，武田制药的控股子公司Myovant在美国上市了120mg规格，用于治疗成人晚期前列腺癌，这一规格在美国、欧盟等各国均有上市，但偏偏未选择在日本上市。 2021年，Myovant和辉瑞联合在美国上市了一款复方制剂，用于治疗女性子宫肌瘤和用于治疗子宫内膜异位症，同时Myovant与匈牙利瑞克特公司合作在欧盟上市了同款复方制剂，此复方制剂同样未在日本上市。 2022年，住友制药收购了Myovant公司，故而Myovant持有的几款产品持有人变更为了住友制药，武田仅保留40mg规格产品以及其他规格的亚洲权益。据住友披露，2024年，Orgovyx销售额约5.3亿美元，Myfembree约8万美元，Ryeqo约831万美元，市场最好的是120mg规格，适应症为成人前列腺癌。然而这几个规格的瑞卢戈利片及复方，均未在国内上市。如上文所说，武田保留了瑞卢戈利片亚洲区的权益，但没有一个规格在国内有上市，2018年，武田公示其在中国登记了120mg规格瑞卢戈利片用于晚期前列腺癌的Ⅲ期期临床试验，于2023年完成试验，但却并未提交上市。目前，瑞卢戈利片40mg和120mg规格均已被列入参比目录，但这个品种仿制成本的确不低，适应症太多，患者群体不同，参比也不同，因此Ⅲ期临床得做多次。从目前申报的临床来看，首家报产企业江西山香药业只布局了120mg规格，进行了治疗成人晚期前列腺癌患者适应症的Ⅲ期试验。而齐鲁则不同，同时申报了两个规格，子宫肌瘤和晚期前列腺癌适应症的临床均在同步进行中。图源：摩熵医药除此之外的企业基本都选择了先做一项适应症的策略，先上市再考虑增适应症，注意到民生于今年提交了一个新的临床申请，猜测可能是前列腺癌适应症。总言之，瑞卢戈利片专利在武田制药手上，化合物专利已到期，江西香山的仿制药上市申请发的是1类专利声明，国内瑞卢戈利片基本不受专利限。竞争愈发激烈，目前就看谁能率先上市了。 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

临床3期并购申请上市临床成功

2026-01-14

·药通社

齐鲁和正大天晴，抢首仿！

1月8日，据CDE官网公示，齐鲁制药（海南）有限公司按化药注册分类3类申报的噁拉戈利片上市申请获受理，这是继正大天晴后第二家提交上市的企业。齐鲁和正大天晴，这两大仿制药巨头又一次在同一个品种上展开竞争。齐鲁和正大天晴，常常同时竞争同一品种的首仿，还发生过多次两家同一日过评的情况。 2023年，培唑帕尼片，齐鲁和正大天晴同一日过评，同日获批并列国内首仿；2024年，艾曲泊帕乙醇胺片，两家企业又是同日首仿。首仿申报时间上更是咬的紧，苯磺酸美洛加巴林片、达格列净二甲双胍缓释片、磷酸芦可替尼片等等，均是前后脚申报上市。那么此次被齐鲁和正大天晴争相仿制的噁拉戈利片是个什么产品？噁拉戈利（又名艾拉戈利钠片）是促性腺激素释放激素（GnRH）受体拮抗剂，主要用于治疗与子宫内膜异位症相关的中度至重度疼痛，原研企业是艾伯维，2018年在美国上市，商品名ORILISSA，原研一直未在国内上市。 ORILISSA是十多年来首个获FDA批准的用于治疗中重度子宫内膜异位症相关疼痛的口服疗法。上市后销售额逐年增长，艾伯维年报在2021年提及ORILISSA年销售额1.45亿美元，后续艾伯维未再单独公布其销售额。图源：艾伯维2021年年报子宫内膜异位症油被称为女性“良性的癌症”，常见临床表现包括痛经、不孕症、慢性盆腔痛等，有文献统计，全球约有1.9亿女性患有子宫内膜异位症，但长期以来，这一疾病始终没有安全有效的治疗手段。而ORILISSA是少有的明确适应症为子宫内膜异位症的药物。 2021年，噁拉戈利被收载于国家《第二批鼓励仿制药品目录》。虽然被收录在鼓励仿制目录里，且ORILISSA的专利已全部到期，但是真正布局这一品种的企业却不多。这一品种仿制需要完成Ⅲ期临床+BE试验，2022年8月，齐鲁最早开始进行Ⅲ期临床，2023年7月正大天晴才开始招募，但齐鲁的临床进展非常慢，受试者研究用了八百多天，最终被正大天晴抢了先机。 2025年8月，正大天晴完成噁拉戈利所有临床试验后率先提交了上市申请，抢先齐鲁一步。齐鲁和正大天晴是目前进度最快的企业，另有5家企业获得临床批件，分别是成都倍特、华海药业、丽珠集团、金美济药业和金陵药业，但无Ⅲ期进度。另外共有5家企业的原料已登记，南通常佑、山东朗诺、奥锐特、乐普和诚达。 ORILISSA虽然是少有可以治疗子宫内膜异位症的药物，但并非十全十美，研究表明长期使用ORILISSA，会造成骨密度损失，且停药后不可逆，说明书写明ORILISSA治疗最长周期在24个月。另一方面ORILISSA在美国的定价很高，月均治疗费接近1000美元，因此销售虽稳步增长，但较此前设想的市场规模还有不小差距。或许这也是国内仿制企业布局不多的主要原因之一。图：ORILISSA英文说明书子宫内膜异位症患者基数不小，但药物很少，幸而近些年进展缓慢的子宫内膜异位症研究终于开始有了进步。 2023年匈牙利瑞克特公司和日本住友制药联合研发推出了RYEQO，在欧盟获批用于治疗子宫内膜异位症， RYEQO是组合制剂，由瑞卢戈利+雌二醇+醋酸炔诺酮组成。目前该组合尚无人仿制，但其中的成分瑞卢戈利片，是国内当前热门仿制产品，也被纳入国家第三批鼓励仿制目录。瑞卢戈利片同样需要完成Ⅲ期临床+BE试验，目前已有12家企业获得临床批件，进度最快的是江西香山，首家提交了上市申请。齐鲁已获瑞卢戈利片临床批件，Ⅲ期临床正在进行中，正大天晴完成BE试验，二者在这个品上齐鲁暂时领先。瑞卢戈利片主要用于治疗前列腺癌，与雌激素组合可用于子宫内膜异位症，单品上市后可由医生配合给药，算是与噁拉戈利片形成了竞争。在新药上，国内企业也有了长足发展，2025年12月，和其瑞医药HMI-115获得美国FDA快速通道认定，此前，HMI-115已被CDE纳入突破性治疗药物品种名单，拟定用于治疗子宫内膜异位症相关的中重度疼痛。相信未来必定会有更多能治疗子宫内膜异位症药物诞生。回归到噁拉戈利片来说，能被齐鲁和正大天晴两大仿制药巨头一起看中的品种，必然存在一定市场价值，虽然目前齐鲁落后一步，但最终的结果谁输谁赢还未定，目前国内相关药物市场相对较小，仍有很大开发空间。参考：氨基观察、邴药说、今日医药 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

2026-01-02

·EINPresswire

July - September 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

ADZYNMA (ADAMTS13, recombinant-krhn) Neutralizing antibodies with fatal outcome FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on November 21, 2025: FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura Asceniv (immune globulin intravenous, human-slra) Increased hypersensitivity reactions in patients receiving certain product lot FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on October 28, 2025: Immune Globulin Intravenous (IGIV) and/or Immune Globulin Subcutaneous (IGSC) Lots with Increased Reports of Allergic/Hypersensitivity Reactions Benlysta (belimumab) injection Severe cutaneous adverse reactions FDA is evaluating the need for regulatory action. Braftovi (encorafenib) capsules Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablet Sarcoidosis FDA is evaluating the need for regulatory action. Cabometyx (cabozantinib) tablets Cometriq (cabozantinib) capsules Lenvima (lenvatinib) capsules Thrombotic microangiopathy FDA is evaluating the need for regulatory action. Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Sarcoidosis FDA is evaluating the need for regulatory action. ELEVIDYS (delandistrogene moxeparvovec-rokl) Mesenteric vein thrombosis following product-related acute liver injury The "Warnings and Precautions" and "Adverse Reactions - Postmarketing Experience" sections of the labeling for Elevidys were updated in November 2025 to include life-threatening mesenteric vein thrombosis. FDA Safety Communication was issued on November 14, 2025: FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment with Elevidys and Revised Indication that is Limited to Ambulatory Duchenne Muscular Dystrophy Patients Firmagon (degarelix for injection) Myfembree (relugolix, estradiol, and norethindrone acetate) tablets Orgovyx (relugolix) tablets Drug interaction FDA is evaluating the need for regulatory action. Ifex (ifosfamide) injection Pregnancy, puerperium and perinatal conditions FDA is evaluating the need for regulatory action. Ogsiveo (nirogacestat) tablets Visual impairment FDA is evaluating the need for regulatory action. Orgovyx (relugolix) tablets Hypertension FDA is evaluating the need for regulatory action. Rezzayo (rezafungin for injection) Hypersensitivity The "Warnings and Precautions", "Adverse Reactions" and "Patient Counseling Information" sections of the labeling were updated in December 2025 to include information about hypersensitivity reactions, including anaphylaxis. Rezzayo labeling Septocaine (articaine hydrochloride and epinephrine injection) Mepivacaine hydrochloride injection (a particular generic product) Wrong drug administered FDA is evaluating the need for regulatory action. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准生物类似药

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H01CC	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	加拿大	Sumitomo Pharma Switzerland GmbH	2023-10-17
出血	加拿大	Sumitomo Pharma Switzerland GmbH	2023-09-22
子宫内膜异位症	美国	Sumitomo Pharma America, Inc.	2022-08-05
月经过多	美国	Sumitomo Pharma America, Inc.	2021-05-26
子宫肌瘤	美国	Sumitomo Pharma America, Inc.	2021-05-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
避孕	临床3期	美国	Sumitomo Pharma Co., Ltd.	2021-03-18
痛经	临床3期	美国	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	澳大利亚	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	巴西	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	智利	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	捷克	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	意大利	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	新西兰	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	波兰	Sumitomo Pharma Switzerland GmbH	2017-11-01
痛经	临床3期	罗马尼亚	Sumitomo Pharma Switzerland GmbH	2017-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03103087 \| NCT03049735 (LIBERTY 1, Pubmed \| Fertil Steril)	临床3期	子宫腺肌病 \| 子宫肌瘤	111	Relugolix combination therapy	簾憲醖構齋鏇鬱築鑰築(夢鑰獵鹹醖鹽鑰製積鏇) = 獵憲壓膚蓋鹹築蓋範積膚餘廠襯餘膚鬱範襯膚 (醖糧襯衊築膚齋廠構衊 ) 更多	积极	2025-09-01
				Placebo	簾憲醖構齋鏇鬱築鑰築(夢鑰獵鹹醖鹽鑰製積鏇) = 繭夢積憲鏇觸淵齋鹽艱膚餘廠襯餘膚鬱範襯膚 (醖糧襯衊築膚齋廠構衊 ) 更多
NCT03103087 (CTgov)	临床3期	月经过多 \| 子宫肌瘤	382	Relugolix+Estradiol/norethindrone acetate (Relugolix Plus E2/NETA (Group A))	壓遞膚艱壓淵鑰鏇積獵 = 鹽繭衊艱糧鹹膚選鑰範積淵觸顧衊餘鬱鬱鬱衊 (蓋餘繭積淵簾廠顧積觸, 齋醖鹹簾選築糧蓋衊遞 ~ 艱醖齋構範範壓窪鏇壓) 更多	-	2022-04-20
				Estradiol/norethindrone acetate placebo (Placebo (Group C))	壓遞膚艱壓淵鑰鏇積獵 = 夢蓋糧衊壓製窪齋壓廠積淵觸顧衊餘鬱鬱鬱衊 (蓋餘繭積淵簾廠顧積觸, 糧衊構衊選願構窪繭淵 ~ 齋觸願觸繭糧遞簾壓餘) 更多
NCT03049735 (LIBERTY 1, CTgov)	临床3期	月经过多 \| 子宫肌瘤	388	Relugolix+Estradiol/norethindrone acetate (Relugolix Plus E2/NETA (Group A))	鑰餘夢選鹹醖鏇鑰壓選 = 獵蓋鹽鹽壓醖憲鏇餘網鏇簾範衊鏇醖襯簾鏇夢 (艱簾襯壓糧鹹膚築鑰壓, 繭網淵淵製築願鹽壓製 ~ 積觸獵憲鹹簾鏇鏇齋製) 更多	-	2022-04-19
				Estradiol/norethindrone acetate placebo (Placebo (Group C))	鑰餘夢選鹹醖鏇鑰壓選 = 淵簾鏇艱觸積餘觸膚蓋鏇簾範衊鏇醖襯簾鏇夢 (艱簾襯壓糧鹹膚築鑰壓, 醖襯觸範築襯築網齋醖 ~ 構繭淵鹽憲範築淵膚簾) 更多